Equities
TechnologyTechnology
  • Price (USD)63.32
  • Today's Change-0.48 / -0.75%
  • Shares traded613.36k
  • 1 Year change-2.18%
  • Beta0.9105
Data delayed at least 15 minutes, as of Jun 15 2024 00:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KBR, Inc. is engaged in delivering science, technology and engineering solutions to governments and companies around the world. The Company's Government Solutions segment provides full life-cycle support solutions to defense, intelligence, space, aviation and other programs and missions for military and other government agencies primarily in the United States, United Kingdom, and Australia. The Company’s Sustainable Technology Solutions segment is anchored by its portfolio of over 80 proprietary, sustainability-focused process technologies that accelerate and enable energy transition across the industrial base in four primary verticals: ammonia/syngas, chemical/petrochemicals, clean refining and circular process/circular economy solutions. The segment also provides highly synergistic services, including advisory and consulting. The Company provides services to a diverse customer base, including domestic and foreign governments and commercial and industrial companies.

  • Revenue in USD (TTM)7.07bn
  • Net income in USD-258.00m
  • Incorporated2006
  • Employees34.00k
  • Location
    KBR IncSUITE 3400, 601 JEFFERSON STREETHOUSTON 77002United StatesUSA
  • Phone+1 (713) 753-3834
  • Fax+1 (302) 655-5049
  • Websitehttps://www.kbr.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Blueprint Medicines Corp282.21m-288.29m6.61bn645.00--21.27--23.42-4.82-4.824.594.960.24990.35316.18430,853.40-25.53-29.92-30.68-34.0696.97---102.15-116.653.61-23.370.4352--22.2241.149.06--4.85--
Repligen Corp607.45m14.84m7.02bn1.78k497.663.5683.1011.560.25240.252410.7435.290.22551.434.87340,689.800.5514.380.61795.0347.7355.432.4415.915.24--0.22840.00-20.3126.91-77.6420.1324.99--
Jazz Pharmaceuticals PLC3.84bn330.79m7.12bn2.80k23.291.937.271.854.854.8555.4958.650.34360.64285.781,372,634.002.991.483.361.6289.5388.798.694.261.902.000.6070.004.7815.19285.14-1.49-20.04--
Intra-Cellular Therapies Inc513.93m-110.87m7.15bn610.00--11.02--13.92-1.15-1.155.346.150.69961.674.83842,508.20-15.09-38.27-17.67-42.7792.82---21.57-128.425.00--0.00--85.51--45.49---7.22--
Bellring Brands Inc1.84bn191.50m7.20bn420.0038.38--30.443.911.441.4413.84-1.902.405.408.714,389,286.0024.9118.8931.72--32.7432.4410.3910.101.845.071.420.0021.5315.03101.0913.80-18.48--
Cerevel Therapeutics Holdings Inc0.00-460.47m7.57bn355.00--13.38-----2.72-2.720.003.100.00----0.00-44.76---48.20--------------0.3745-------23.14------
Exact Sciences Corp2.53bn-240.23m7.73bn6.50k--2.46--3.05-1.32-1.3213.9317.040.39985.2811.96389,975.40-3.79-9.71-4.13-10.6073.6774.10-9.48-28.211.45--0.4323--19.9340.6367.26---3.71--
Legend Biotech Corp (ADR)342.80m-465.95m7.74bn1.80k--6.65--22.57-2.60-2.601.906.390.22979.52203.86190,443.30-31.22-37.71-37.33-47.1952.35---135.92-286.515.57-24.440.2233--143.7042.15-16.11--1.57--
Roivant Sciences Ltd124.80m4.35bn7.90bn845.002.111.441.8663.285.075.070.15717.400.0260.81872.97147,686.4088.04--103.92--87.53--3,390.53--25.10--0.0642--103.65--487.06------
Vaxcyte Inc0.00-436.82m7.94bn254.00--4.00-----4.22-4.220.0018.240.00----0.00-28.19-34.22-29.52-37.21------------0.00-------80.00--107.28--
KBR Inc7.07bn-258.00m8.50bn34.00k--6.06--1.20-1.91-1.9152.6710.461.25--5.56207,970.60-4.450.4725-6.460.667813.8612.18-3.580.4122--1.170.5678340.005.977.20-240.21--36.3111.03
Elanco Animal Health Inc4.37bn-1.30bn8.91bn9.30k--1.47--2.04-2.64-2.648.8412.260.29311.214.28469,354.80-8.74-3.27-9.65-3.6555.2854.28-29.83-11.531.960.8530.4877--0.1367.57-1,478.21--2.74--
Catalent Inc4.14bn-1.18bn10.04bn17.80k--2.77--2.43-6.48-6.4822.6920.060.39934.362.87232,303.40-11.362.88-12.913.2618.9631.03-28.446.351.74-0.43460.57970.00-11.2211.59-153.00--26.69--
Insmed Inc315.49m-746.89m10.42bn912.00------33.04-5.23-5.232.20-3.130.23570.89719.32345,936.40-55.80-40.96-72.23-46.8878.0777.99-236.74-212.921.61-16.081.64--24.3998.78-55.66---2.15--
Data as of Jun 15 2024. Currency figures normalised to KBR Inc's reporting currency: US Dollar USD

Institutional shareholders

48.23%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 202418.09m13.39%
The Vanguard Group, Inc.as of 31 Mar 202412.81m9.48%
BlackRock Fund Advisorsas of 31 Mar 202411.23m8.32%
Massachusetts Financial Services Co.as of 31 Mar 20245.24m3.88%
Invesco Advisers, Inc.as of 31 Mar 20244.08m3.02%
SSgA Funds Management, Inc.as of 31 Mar 20244.04m2.99%
Snyder Capital Management LPas of 31 Mar 20242.61m1.93%
Permian Investment Partners LPas of 31 Mar 20242.51m1.86%
Franklin Mutual Advisers LLCas of 31 Mar 20242.34m1.73%
Neuberger Berman Investment Advisers LLCas of 31 Mar 20242.19m1.62%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.